ARCHIVES

Risk-Benefit Analysis Advised Prior To Hormone Therapy

This article is from The Cancer Letter archive.

Vol. 33 No. 8 | August 27, 2010

Download PDF Visit The Full Archive

Related Articles

Mayo Clinic’s NCI Designation Extended To Arizona, Florida Sites

July 26, 2002

Combination Therapy Improves Survival For HIV+ Patients

February 24, 2006

FDA Updates Safety Information for 5-Alpha Reductase Inhibitors

June 17, 2011

NCAB Approves Fallout Study On Split Vote

March 13, 1981

Kadcyla Extends Median PFS In Open-Label Phase III Trial

October 25, 2013

Medenica Granted Extension Of Privileges At Hilton Head Hospital

November 26, 1993